Periostin as a promising biological marker of early recurrence of polyposis rhinosinusitis after surgical treatment

Introduction. In spite of the numerous studies devoted to the issues of chronic rhinosinusitis with nasal polyps, the urgency of this problem remains due to the high incidence of the disease. The relapsing course of chronic rhinosinusitis with nasal polyps determines the uncontrolled course of bronchial asthma by patients with combined pathology. The main goal of case management of patients with chronic rhinosinusitis with nasal polyps is to achieve control over the polyposis process. It has been shown, that a promising direction is the study of biological markers. Goal. Study of the concentration of serum periostin in combination with serum eosinophilia and the number of eosinophils of the nasal secretion to predict early recurrence of chronic rhinosinusitis with nasal polyps after surgical treatment.

Materials and methods. The study included 47 patients with a diagnosis of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis with nasal polyps in combination with bronchial asthma. All patients underwent bilateral endoscopic polysinusotomy followed by case follow-up for a year. The diagnosis of bronchial asthma was made based on the diagnostic criteria defined in the Global Strategy for the Treatment and Prevention of Bronchial Asthma and in the Federal Clinical Guidelines for the Diagnosis and Treatment of Bronchial Asthma. All patients were consulted by a pulmonologist. Control examinations of patients were carried out every 3 months. All patients underwent a study of the concentration of periostin in the blood serum. Blood probe samples were taken before the start of treatment and after 12 months.

Results and discussion. In the course of the study, was proved the relationship between a high concentration of serum periostin in combination with increased eosinophils of blood and nasal secretion with an early relapse of polyposis rhinosinusitis.

Conclusions. An increased concentration of serum periostin before surgical treatment is a prognostically unfavorable factor for early recurrence of chronic rhinosinusitis with nasal polyps.

1. Egorov V.I., Lopatin A.S., Piskunov G.Z., Ryazantsev S.V. Polypoid Rhinosinusitis: Clinical Guidelines. Moscow: Ministry of Health of the Russian Federation, 2019. 34 p. (In Russ.) Available at: http://glav-otolar.ru/assets/images/docs/clinical-recomendations/2019/Полипозный%20риносинусит.pdf.

2. London N.R., Reh D.D. Differential Diagnosis of Chronic Rhinosinusitis with Nasal Polyps. Adv Otorhinolaryngol. 2016;79:1–12. doi: 10.1159/000444957.

3. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(S29 Suppl.):1–464. doi: 10.4193/rhin20.600.

4. Chichkova N.V. Bronchial Asthma and Diseases of the Nasal Cavity and Paranasal Sinuses: the Unity of Pathological Processes in the Respiratory System. RMZH = RMJ. 2015;(18):1132–1136. (In Russ.) Available at: https://rmj.ru/articles/bolezni_dykhatelnykh_putey/Bronhialynaya_astma_i_zabolevaniya_polosti_nosa_i_okolonosovyh_pazuh_edinstvo_patologicheskih_processov_v_dyhatelynoy_sisteme/#ixzz6smwhyCte

5. Frendø M., Håkansson K., Schwer S., Rix I., Ravn A.T., Backer V. et al. Asthma in Ear, Nose, and Throat Primary Care Patients with Chronic Rhinosinusitis with Nasal Polyps. Am J Rhinol Allergy. 2016;30(3):e67–e71. doi: 10.2500/ajra.2016.30.4304.

6. Tan E., Varughese R., Semprini R., Montgomery B., Holweg C., Olsson J. et al. Serum Periostin Levels in Adults of Chinese Descent: An Observational Study. Allergy Asthma Clin Immunol. 2018;14:87. doi: 10.1186/s13223-018-0312-3.

7. Wagener A.H., De Nijs S.B., Lutter R., Sousa A.R., Weersink E.J.M., Bel E.H. et al. External Validation of Blood Eosinophils, FENO and Serum Periostin as Surrogates for Sputum Eosinophils in Asthma. Thorax. 2015;70(2):115– 120. doi: 10.1136/thoraxjnl-2014-205634.

8. Lund V.J., Flood J., Sykes A.P., Richards D.H. Effect of Fluticasone in Severe Polyposis. Arch Otolaryngol Head Neck Surg. 1998;124(5):513–518. doi: 10.1001/archotol.124.5.513.

9. Chong L.Y., Head K., Hopkins C., Philpott C., Burton M.J., Schilder A.G.M. Different Types of Intranasal Steroids for Chronic Rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011993. doi: 10.1002/14651858.CD011993.pub2.

10. Head K., Chong L.Y., Hopkins C., Philpott C., Burton M.J., Schilder A.G.M. Short-Course Oral Steroids Alone for Chronic Rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011991. doi: 10.1002/14651858.CD011991.pub2.

11. Kalish L., Snidvongs K., Sivasubramaniam R., Cope D., Harvey R.J. Topical Steroids for Nasal Polyps. Cochrane Database Syst Rev. 2012;12:CD006549. doi: 10.1002/14651858.CD006549.pub2.

12. Martinez-Devesa P., Patiar S. WITHDRAWN: Oral Steroids for Nasal Polyps. Cochrane Database Syst Rev. 2016;4:CD005232. doi: 10.1002/14651858.CD005232.pub4.

13. Jafari A., Deconde A.S. Outcomes in Medical and Surgical Treatment of Nasal Polyps. Adv Otorhinolaryngol. 2016;79:158–167. doi: 10.1159/000445155.

14. Thompson C.F., Price C.P.E., Huang J.H., Min J.Y., Suh L.A., Shintani-Smith S. et al. A Pilot Study of Symptom Profiles from a Polyp vs an EosinophilicBased Classification of Chronic Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(5):500–507. doi: 10.1002/alr.21687.

15. Lou H., Meng Y., Piao Y., Zhang N., Bachert C., Wang C. et al. Cellular Phenotyping of Chronic Rhinosinusitis with Nasal Polyps. Rhinology. 2016;54(2):150–159. doi: 10.4193/Rhin15.271.

16. Kawamoto T., Noshiro M., Shen M., Nakamasu K., Hashimoto K., Kawashima-Ohya Y. et al. Structural and Phylogenetic Analyses of RGDCAP/beta ig-h3, a Fasciclin-Like Adhesion Protein Expressed in Chick Chondrocytes. Biochim Biophys Acta. 1998;1395(3):288–292. doi: 10.1016/s0167-4781(97)00172-3.

17. Conway S.J., Izuhara K., Kudo Y., Litvin J., Markwald R., Ouyang G. et al. The Role of Periostin in Tissue Remodeling across Health and Disease. Cell Mol Life Sci. 2014;71(7):1279–1288. doi: 10.1007/s00018-013-1494-y.

18. Ishida A., Ohta N., Suzuki Y., Kakehata S., Okubo K., Ikeda H. et al. Expression of Pendrin and Periostin in Allergic Rhinitis and Chronic Rhinosinusitis. Allergol Int. 2012;61(4):589–595. doi: 10.2332/allergolint.11-OA-0370.

19. Nishizawa H., Matsubara A., Nakagawa T., Ohta N., Izuhara K., Shirasaki T. et al. The Role of Periostin in Eosinophilic Otitis Media. Acta Otolaryngol. 2012;132(8):838–844. doi: 10.3109/00016489.2012.668708.

20. Takayama G., Arima K., Kanaji T., Toda S., Tanaka H., Shoji S. et al. Periostin: A Novel Component of Subepithelial Fibrosis of Bronchial Asthma Downstream of IL-4 and IL-13 Signals. J Allergy Clin Immunol. 2006;118(1):98–104. doi: 10.1016/j.jaci.2006.02.046.

21. Sidhu S.S., Yuan S., Innes A.L., Kerr S., Woodruff P.G., Hou L. et al. Roles of Epithelial Cell-Derived Periostin in TGF-β Activation, Collagen Production, and Collagen Gel Elasticity in Asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170–14175. doi: 10.1073/pnas.1009426107.

22. Yuyama N., Davies D.E., Akaiwa M., Matsui K., Hamasaki Y., Suminami Y. et al. Analysis of Novel Disease-Related Genes in Bronchial Asthma. Cytokine. 2002;19(6):287–296. doi: 10.1006/cyto.2002.1972.

23. Blanchard C., Mingler M.K., McBride M., Putnam P.E., Collins M.H., Chang G. et al. Periostin Facilitates Eosinophil Tissue Infiltration in Allergic Lung and Esophageal Responses. Mucosal Immunol. 2008;1(4):289–296. doi: 10.1038/mi.2008.15.

24. Masuoka M., Shiraishi H., Ohta S., Suzuki S., Arima K., Aoki S. et al. Periostin Promotes Chronic Allergic Inflammation in Response to Th2 Cytokines. J Clin Invest. 2012;122(7):2590–2600. doi: 10.1172/JCI58978.

25. Matsumoto H. Serum Periostin: A Novel Biomarker for Asthma Management. Allergol Int. 2014;63(2):153–160. doi: 10.2332/allergolint.13-RAI-0678.

26. Uchida M., Shiraishi H., Ohta S., Arima K., Taniguchi K., Suzuki S. et al. Periostin, A Matricellular Protein, Plays a Role in the Induction of Chemokines in Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2012;46(5):677–686. doi: 10.1165/rcmb.2011-0115OC.

27. Jia G., Erickson R.W., Choy D.F., Mosesova S., Wu L.C., Solberg O.D. et al. Periostin Is a Systemic Biomarker of Eosinophilic Airway Inflammation In asthmatic Patients. J Allergy Clin Immunol. 2012;130(3):647.e10–654.e10. doi: 10.1016/j.jaci.2012.06.025.

28. Kanemitsu Y., Matsumoto H., Izuhara K., Tohda Y., Kita H., Horiguchi T. et al. Increased Periostin Associates with Greater Airflow Limitation in Patients Receiving Inhaled Corticosteroids. J Allergy Clin Immunol. 2013;132(2):305. e3–312.e3. doi: 10.1016/j.jaci.2013.04.050.

29. Ishida A., Ohta N., Koike S., Aoyagi M., Yamakawa M. Overexpression of Glucocorticoid Receptor-β in Severe Allergic Rhinitis. Auris Nasus Larynx. 2010;37(5):584–588. doi: 10.1016/j.anl.2009.12.002.

30. Chuchalin A.G., Avdeev S.N., Aysanov Z.R., Belevskiy A.S., Vasilyeva O.S., Geppe N.A. et al. Bronchial Asthma: Clinical Guidelines. Moscow; 2019. 97 p. (In Russ.) Available at: https://spulmo.ru/upload/kr_bronhastma_2019.pdf.